Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Paul M Mendelman"'
Autor:
Lisa C Lindesmith, Martin T Ferris, Clancy W Mullan, Jennifer Ferreira, Kari Debbink, Jesica Swanstrom, Charles Richardson, Robert R Goodwin, Frank Baehner, Paul M Mendelman, Robert F Bargatze, Ralph S Baric
Publikováno v:
PLoS Medicine, Vol 12, Iss 3, p e1001807 (2015)
BackgroundHuman noroviruses (NoVs) are the primary cause of acute gastroenteritis and are characterized by antigenic variation between genogroups and genotypes and antigenic drift of strains within the predominant GII.4 genotype. In the context of th
Externí odkaz:
https://doaj.org/article/4016f38867184ad8a67bb1f357cc1355
Autor:
Pio López, Eduardo López-Medina, Xavier Sáez-Llorens, Rodrigo deAntonio, Taisei Masuda, Paul M. Mendelman, James Sherwood, Frank Baehner, Astrid Borkowski
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6–≤12 months and 1–≤4 years of age (N = 120 per cohort), in Panama and Colombia (ClinicalTria
Externí odkaz:
https://doaj.org/article/8bdc7287d8f147359bc3a2bc68a345d5
Autor:
Timo Vesikari, Xavier Saez-Llorens, Vezna Blazevic, Pio Lopez, Eduardo Lopez, Taisei Masuda, Paul M. Mendelman, Mengya Liu, James Sherwood, Frank Baehner, Astrid Borkowski
Publikováno v:
Vaccine. 40(26)
Background: Young children can suffer severe consequences of norovirus gastroenteritis. We performed a dose-finding study of a bivalent virus-like particle (VLP) vaccine candidate (TAK-214) in healthy 1–8-year-old children. Methods: In this phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6795593555aae92fb118d0d0ca835d00
https://pubmed.ncbi.nlm.nih.gov/35595661
https://pubmed.ncbi.nlm.nih.gov/35595661
Autor:
Dennis J. Faix, Eric E. Lloyd, Paul M. Mendelman, Astrid Borkowski, Mengya Liu, John Boslego, Ashley Jackson, James Sherwood
Publikováno v:
Vaccine. 38(41)
Background We performed this first-in-human efficacy trial of Takeda’s bivalent norovirus vaccine candidate (TAK-214) against moderate or severe acute gastroenteritis (AGE) in healthy adults. Methods This double-blind, randomized, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87462ff0ad7dadabc1c5065f54715b93
https://pubmed.ncbi.nlm.nih.gov/32878708
https://pubmed.ncbi.nlm.nih.gov/32878708
Autor:
Robert L, Atmar, Frank, Baehner, Jakob P, Cramer, Eric, Lloyd, James, Sherwood, Astrid, Borkowski, Paul M, Mendelman, John J, Treanor
Publikováno v:
The Journal of infectious diseases. 220(4)
BackgroundWe previously reported the tolerability and immunogenicity 1 month after intramuscular administration of 2 bivalent virus-like particle (VLP)–based candidate norovirus vaccine formulations in adults. We now describe the persistence of imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc891244b7fd210dbf12af840e6b9462
https://pubmed.ncbi.nlm.nih.gov/31001633
https://pubmed.ncbi.nlm.nih.gov/31001633
Autor:
Frank Baehner, Cong Han, Paul M. Mendelman, Robert L. Atmar, Astrid Borkowski, Jakob P Cramer
Publikováno v:
J Infect Dis
As noroviruses are transmitted through the fecal-oral route, we investigated humoral and mucosal (salivary immunoglobulin A [IgA]) immune responses in a phase 2 trial of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed7f9a379bc6f141b97dad05de7bd54e
https://pubmed.ncbi.nlm.nih.gov/30203081
https://pubmed.ncbi.nlm.nih.gov/30203081
Autor:
Christine L. Moe, Jennifer Ferreira, Nicole Gregoricus, Jan Vinjé, David Y. Graham, Jill Barrett, Antone R. Opekun, Mary K. Estes, Astrid Borkowski, Mohamed S. Al-Ibrahim, Frank Baehner, Anthony Edmonds, Robert Goodwin, Robert L. Atmar, G. Marshall Lyon, Robert W. Frenck, David I. Bernstein, Wilbur H. Chen, Xi Jiang, John J. Treanor, Paul M. Mendelman
Publikováno v:
Clinical and Vaccine Immunology. 22:923-929
Noroviruses are the leading cause of acute gastroenteritis worldwide, and norovirus vaccine prevention strategies are under evaluation. The immunogenicity of two doses of bivalent genogroup 1 genotype 1 (GI.1)/GII.4 (50 μg of virus-like particles [V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfb09d4fd73f15bb0cc55f5fb3fe6bc
https://doi.org/10.1128/cvi.00196-15
https://doi.org/10.1128/cvi.00196-15
Autor:
Sharon E. Frey, David J. Topham, Robert L. Atmar, Jennifer Ferreira, Aarthi Sundararajan, Paul M. Mendelman, Wilbur H. Chen, Mark Y. Sangster, Robert F. Bargatze, John J. Treanor
Publikováno v:
Vaccine. 33(4):568-576
Background Two major antigenically heterogenous norovirus genogroups (GI and GII) commonly infect humans and are the leading cause of foodborne, viral gastrointestinal infections in adults. Methods We assessed B cell responses in participants in a do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f482d43a75e23db592db52403233546f
Autor:
Frank Baehner, Pierre Van Damme, Astrid Borkowski, James Sherwood, Jakob P Cramer, Ilse De Coster, Geert Leroux-Roels, Paul M. Mendelman, Ralf Clemens, Annelies Aerssens
Publikováno v:
The Journal of Infectious Diseases
The journal of infectious diseases
The journal of infectious diseases
Bivalent (GI.1 and GII.4) virus-like particle norovirus candidate vaccine formulations were well tolerated and immunogenic, 1 dose inducing immune responses that persisted up to 1 year, which were not increased by inclusion of monophosphoryl lipid A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe8e058563137e9635c6845829c52550
https://pubmed.ncbi.nlm.nih.gov/29140444
https://pubmed.ncbi.nlm.nih.gov/29140444
Autor:
Robert Goodwin, Sasirekha Ramani, Frank Baehner, Astrid Borkowski, Sharon E. Frey, Frederick H. Neill, Robert L. Atmar, Mary K. Estes, John J. Treanor, Paul M. Mendelman, David J. Topham, Jennifer Ferreira
Publikováno v:
Clinical and Vaccine Immunology : CVI
Human noroviruses (HuNoVs) are a leading cause of acute gastroenteritis worldwide. A virus-like particle (VLP) candidate vaccine induces the production of serum histo-blood group antigen (HBGA)-blocking antibodies, the first identified correlate of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8f3e4a4732545f112e238266bc4de6
https://doi.org/10.1128/cvi.00571-16
https://doi.org/10.1128/cvi.00571-16